




Liposomal Combination Drug and siRNA




Follow this and additional works at: https://tigerprints.clemson.edu/all_theses
This Thesis is brought to you for free and open access by the Theses at TigerPrints. It has been accepted for inclusion in All Theses by an authorized
administrator of TigerPrints. For more information, please contact kokeefe@clemson.edu.
Recommended Citation
Miller, Emily Margaret, "Liposomal Combination Drug and siRNA Delivery to Combat Drug-Resistant Ovarian Cancer" (2018). All
Theses. 2997.
https://tigerprints.clemson.edu/all_theses/2997




the Graduate School of 
Clemson University 
In Partial Fulfillment 
of the Requirements for the Degree 
Master of Science 
Bioengineering  
by 
Emily Margaret Miller 
December 2018 
Accepted by: 
Dr. Angela Alexander-Bryant, Ph.D., Committee Chair 
Dr. Brian Booth, Ph.D., 
Dr. Naren Vyavahare, Ph.D.
ii 
ABSTRACT 
Ovarian cancer is the deadliest gynecological malignancy and the fifth leading 
cause of cancer death overall. Due to lack of early symptoms, ovarian cancer is most 
commonly diagnosed in the distant stages, drastically reducing the 5 year survival rate 
from 92% in early stage diagnoses to 29% in advanced stage cases. This large difference 
is thought to be linked to the high rate of recurrence and development of drug 
resistance to chemotherapeutics in ovarian cancer patients. First-line therapy includes a 
combination of tumor resection surgery and chemotherapy regimen including cisplatin, 
a DNA-alkylating agent, and paclitaxel, a microtubule stabilization agent. However, 
treatment becomes more complex upon recurrence due to the development of drug 
resistance. Drug resistance has been linked to many mechanisms, including efflux 
transporters, dysregulation of apoptosis, autophagy, cancer stem cells, epigenetics, and 
the epithelial-mesenchymal transition. Due to the wide variety of mechanisms involved 
in resistance, developing and choosing effective therapies is extremely complex. 
Liposomes demonstrate potential as delivery systems to combat drug-resistance 
in cancer due to their versatility in loading. Liposomes possess the ability to load 
multiple therapeutics to re-sensitize resistant cancer cells while simultaneously treating 
those cells with a chemotherapeutic agent. Here, a liposomal carrier for both paclitaxel 
and siRNA was designed and synthesized to provide a combinatorial therapy to re-
sensitize drug-resistant ovarian cancer cells to paclitaxel and thereby increase the 
efficacy of paclitaxel. A custom siRNA array was developed, and we identified three 
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possible gene targets, ABCB1, JAK2, and CFLAR, involved in the development of drug 
resistance in paclitaxel-resistant OVCAR3-TR ovarian cancer cells.  
Two combinatorial, cationic liposome delivery systems were designed and 
synthesized via the lipid film hydration method. Liposomes were characterized for size, 
surface charge, stability, and loading efficiencies. We demonstrated efficient loading of 
paclitaxel and protection of bound siRNA in both liposome formulations. Cellular uptake 
of the liposomes was confirmed using fluorescence microscopy. Overall, the liposomes 
show promise in loading both paclitaxel and siRNA to target genes involved in drug-
resistance development in ovarian cancer cells.  
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CHAPTER ONE 
INTRODUCTION AND BACKGROUND 
Ovarian cancer is the fifth leading cause of cancer death amongst women and 
the most lethal gynecological cancer [1]. Over 22,200 new diagnoses and 14,000 deaths 
are expected in 2018 [1]. The high death rate of ovarian cancer stems from late 
diagnosis and lack of early symptoms of the disease. Around 60% of ovarian cancer 
diagnoses occur in the distant or advanced stages of the diseases, resulting in a five-year 
survival rate of only 21-29% [1]. However, in localized stages, the five-year survival rate 
is 87-93% [1]. Without diagnostic advancements, there is a significant need to improve 
upon current treatments to accurately target cancer cells and increase the efficacy of 
delivered therapeutic agents.  
Current diagnostics for ovarian cancer utilize cancer antigen 125 (CA-125) serum 
levels, transvaginal ultrasonography, or imaging methods including computed 
tomography (CT) or magnetic resonance imaging (MRI) in order to identify potentially 
cancerous tissue. CA-125 is the most used diagnostic for ovarian cancer because serum 
levels of CA-125 are typically elevated in more advanced stages of the disease [2]. 
However, measuring CA-125 levels alone is often not sufficient in diagnosing ovarian 
cancer without the aid of other methods [2]. The most problematic characteristics of 
CA-125 diagnostics include low sensitivity in stage 1 disease and low specificity due to 
increased CA-125 levels in other cancers and benign conditions, like menstruation, 
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pregnancy, endometriosis, and pelvic inflammatory disease [3]. Imaging methods, 
including CT and MRI, have proven to be more reliable than CA-125 in diagnosis of the 
first recurrence of ovarian cancer when overall survival and progression-free survival 
were compared [4]. Currently, transvaginal ultrasonography is utilized when a patient 
has suspected masses on their pelvis to identify the origin [5].  
Upon diagnosis, the current standard of care for ovarian cancer treatment is a 
combination of cytoreductive surgery and chemotherapy [6]. The order in which these 
treatments occur depends on each patient and is ultimately decided upon by the doctor. 
Combination carboplatin and paclitaxel remains the standard frontline chemotherapy 
treatment for advanced ovarian cancer [7]. The time between initial resection and 
initiation of chemotherapy regimens is a vital factor in predicting the overall survival of 
women with advanced ovarian cancer, with an increased risk of death when the time 
period surpasses 25 days [8]. However, despite first-line treatment, around 70% of 
patients relapse [2]. Recurrent cancer is rarely treated with second-line surgery and the 
focus shifts to chemotherapy instead because more problems arise when treating a 
relapse. Alterations in the sensitivity of cancer cells to chemotherapeutics may occur 
based on prior exposure to each type of therapeutic agent; thus, drug resistance may 
become a challenge in treating recurrent cancer.  
1.1 Drug Resistance Development in Ovarian Cancer 
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 The aggressive nature of advanced ovarian cancer is thought to be correlated to 
the development of resistance to chemotherapeutics to which the patients are exposed. 
High recurrence rates are problematic, but they provide an even greater challenge when 
sensitivity to chemotherapy used in primary treatment decreases during secondary 
treatment. Various factors and pathways influence the sensitivity of cells to drugs; 
therefore, resistance cannot be reversed by only targeting one specific area or pathway. 
In ovarian cancer, the main mechanisms of resistance include membrane transporter 
activity [9], dysregulation of apoptosis [10], autophagy [11], cancer stem cells [12], 
epigenetics [13], and the epithelial-mesenchymal transition [14]. However, other 
unknown underlying factors could also be mediating the development of resistant 
phenotypes. 
 
1.1.1 Membrane Transporter Activity 
 Membrane transporters are involved in maintaining an equilibrium influx and 
efflux of molecules in the cell, where a change in this equilibrium can change the 
phenotype of the cell [15]. Chemoresistant phenotypes arise when a decrease in influx 
of molecules is coupled with an increased efflux due to increasingly active membrane 
transporters, reducing the cellular uptake, intracellular accumulation, and anticancer 
activity of chemotherapeutics. The most studied and well-known culprits of 
chemoresistance are ATP-binding cassette (ABC) membrane transporters, which 





The ABC protein superfamily includes 49 proteins involved in drug resistance 
from seven subfamilies [16]. Multidrug resistance (MDR) has been linked to 
upregulation in ABCB1, ABCC1, and ABCG2, as well as many others [17,18].  ABCB1, also 
known as multidrug resistance protein 1 (MDR1), codes P-glycoprotein (P-gp), a multi-
drug membrane transporter [19]. Normal function of P-gp includes the regulation of 
apoptosis, which can be modified through transporting molecules into or out of the cell 
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[19]. Overexpression of P-gp led to increased cell protection and decreased stem cell 
differentiation, thereby, promoting cancerous activity [19]. 
Expression levels of MDR-related genes in ovarian cancer cells resistant to 
chemotherapy drugs provide a possible parameter to use to analyze cross-resistance 
between cell lines. High P-gp expression levels indicate drug resistance in W1 ovarian 
cancer cell lines resistant to doxorubicin, paclitaxel, and vincristine. BCRP, or ABCG2, 
expression indicates resistance in topotecan-resistant W1 cells [17]. Cross-resistance 
discovered between the paclitaxel- and doxorubicin-resistant cell lines could be 
problematic if doxorubicin is given as a second line treatment for paclitaxel-resistant 
ovarian cancer. The work of Januchowski and colleagues expands upon earlier studies 
demonstrating that P-gp, MDR1, MDR2, and LRP drug resistance-associated markers are 
prognostic factors in ovarian cancer diagnoses [20]. 
 
1.1.2 Dysregulation of Apoptosis 
 Dysregulation of apoptosis pathways in the cell can increase cell survival and 
avoidance of drug-induced death. Numerous signaling pathways are involved in 
controlling apoptosis pathways in a cell, including PI3K/Akt and NF-kB. The Bcl-2 family 
of regulatory proteins mediates cell death by either inhibiting or inducing apoptosis 
through a balance between pro- and anti-apoptotic proteins. Bcl-2 activates the Akt 
pathway activity [21], and the NF-kB signaling pathway has been found to be activated 
by Akt through the presence of mTOR [22]. The upregulation of Bcl-2 anti-apoptotic 
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proteins is characteristic of cancer and increased proliferation and survival of cancer 
cells. In paclitaxel-resistant SKOV3 cells, downregulation of Bcl-2 and hTERT increased 
apoptosis after 6 days of combination treatment with epigallocatechin gallate and 
sulforaphane [23].  
 The upregulation of signaling pathways, like PI3K/Akt and NF-kB, has also been 
found to play an important role in developing resistance to chemotherapy. The 
development of resistance to cisplatin, paclitaxel, and bevacizumab in ovarian cancer 
cell lines has been linked to activation of the Akt pathway. In A2780 cisplatin-resistant 
and CAOV3 cells, blockage of the Akt pathway via gemcitabine treatment inhibited 
cisplatin-induced Akt activation, and co-treatment with cisplatin completely inhibited 
the invasion of both cell lines in matrigel [24]. Also, overexpression of Akt in cisplatin-
resistant A2780 cells led to an increase in cells escaping the natural killer cells of the 
immune system and an increase in the expression of anti-apoptotic proteins, CIAP-1 and 
-2 [25]. 
In paclitaxel-resistant A2780, SKOV3, and MPSC1 cells, the downregulation of the 
Akt and NF-kB pathways through tectorigenin treatment resulted in sensitization of cells 
to paclitaxel and enhanced growth inhibition, compared to paclitaxel treatment alone 
[26]. Tectorigenin also inhibited the nuclear translocation of NF-kB and the expression 
of many NF-kB-dependent genes known to be involved in drug resistance, including FLIP, 
XIAP, Bcl-2, and Bcl-xL [26]. Akt pathway activation in endothelial ovarian cancer cells, 
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OVCAR-3 and SKOV3 cell lines, demonstrated characteristics of a niche for residual 
cancerous tissue with resistance to bevacizumab [27]. 
 
1.1.3 Autophagy 
  In addition, autophagy plays a role in the sensitivity of cancer cells to 
chemotherapy. Autophagy is used by cells to aid in survival under nutrient starvation or 
other cellular stresses through digestion of their own cellular components to maintain 
energy. Cells can use autophagy as a protective mechanism against stresses, like the 
damaging effects of chemotherapy, resulting in decreased anticancer response [28]. 
Cisplatin-resistant ovarian cancer cells, OV433-CR, demonstrated increased activation of 
the ERK pathway, which promotes autophagy induction. Inhibition of ERK/MAPK activity 
decreased autophagy and increased sensitivity of cells to cisplatin-induced death [29]. 
The inhibition of autophagy in cisplatin-resistant SKOV3 and A2780 cells also increased 
apoptosis via the overexpression of miR-152, an autophagy-regulating miRNA involved 
in cisplatin resistance [30]. 
Reactive oxygen species (ROS) maintenance is vital in all cells in order to respond 
to environmental changes. When ROS production increases past an allowable threshold, 
the expected outcome is cell death. However, there is a suspected relationship between 
autophagy and ROS production. Autophagy is believed to be a protective mechanism 
when dealing with stress and ROS generation in ovarian cancer cells, increasing as ROS 
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increases [31]. This extended protection may provide cancer cells a longer time to repair 
DNA damage from chemotherapy, thus decreasing the efficacy of chemotherapeutics. 
 
1.1.4 Cancer Stem Cells 
Autophagy also plays a role in mediating chemoresistance of cancer stem cells 
(CSCs) [11]. A recent discovery proved that cancer stem cells are involved in the 
development of drug resistance due to their stem cell-like phenotype (Fig. 1.2). 
Particularly, their ability to resist apoptosis by DNA damage prolongs the survival of 
cancer stem cells in cancer tissue [10]. Cancer stem cell phenotypes include 
characteristic evasion of apoptosis in hypoxic conditions, increased growth potential 
[32], and increased CSC marker aldehyde dehydrogenase isoform 1 activity [33]. CSCs 
from the HO8910 cell line demonstrated faster growth and enhanced survival potential 
in a 3D cell culture as well as increased tumorigenicity in a xenograft mouse model 
compared to the parental HO8910 cells. Also, CSCs showed increased resistance to 5-
fluorouracil, cisplatin, and carboplatin as well as high expression of MDR genes, ABCB1, 
ABCG2, MMP2, and MMP9 [32]. Recent efforts have explored the mediation of drug 
resistance via cancer stem cell elimination. In SKOV3-spheroid cells, knockdown of KLF5 
is a promising target to eliminate CSCs, shown by a decrease in survivin expression and 
increase in sensitivity to paclitaxel and cisplatin [34]. 
Aldehyde dehydrogenase isoform 1 (ALDH1) is an emerging marker, which when 
used in combination with other stem cell markers, can identify populations of cancer 
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stem cell populations in ovarian cancer. ALDH1 activity, measured by fluorescently-
labeled ALDH1, showed ALDH1-bright cells were more common in ES-2 and CP70 
ovarian cancer cell lines and showed increased chemoresistance compared to SKOV3, 
OVCAR3, and A2780 ovarian cancer cells that did not express high levels of ALDH1 [35]. 
Tumor samples from 84 subjects indicated the association of cancer stem cell marker 
ALDH1 with chemoresistance and poor clinical outcomes in epithelial ovarian cancer 








Epigenetics and other changes in the tumor microenvironment, including DNA 
methylation, histone modification, and microRNA expression, have become greater 
focuses in the drug resistance mechanisms of ovarian cancer over the last decade [13]. 
Current studies are exploring various miRNAs and DNA modifications in order to exploit 
specific pathways involved in the development of chemoresistance in ovarian cancer 
[36,37]. DNA methylation involves the addition of a methyl group to DNA without 
changing the sequence, but when methylation occurs in the promoter region of a gene, 
the gene can be repressed. Hypermethylation of genes is common in drug-resistant 
ovarian cancer cells, including A2780 cells resistant to cisplatin. In a study of the 
methylome and gene expression in wild-type and resistant A2780 cells, 13 out of 41 
genes were consistently upregulated in the A2780/CP70 cisplatin-resistant ovarian 
cancer cells compared to parental A2780 ovarian cancer cells, where initially 
methylated-MLH1, a DNA repair gene, played a role in re-sensitizing cells to cisplatin 
when demethylated in vitro [38]. DNA methylation has been found to interfere with 
cisplatin-sensitivity in both A2780 and OVCAR3 cells through overexpression of MAFG, a 
DNA binding transcription factor. MAFG expression can be directly regulated by miR-7, 
creating a potential target for mediating drug resistance with MAFG and a factor for 
prognosis in the methylation status of miR-7 [39]. 
Furthermore, epigenetic silencing, or the process of non-mutational change in 
gene expression that can be passed down from generation to generation in cells [40], 
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continues to reveal prognostic biomarkers and potential therapeutic targets in drug-
resistant ovarian cancer cells. Epigenetic silencing of miR-199b-5p in cisplatin-resistant 
A2780 and C13* cells demonstrated activation of the JAG1-mediated Notch1 signaling 
pathway, encouraging the development of chemoresistance. Downregulation of miR-
199b-5p is associated with poor clinical outcomes in ovarian cancer patients; thus, 
microRNA levels could be a prognostic factor and JAG1 a therapeutic target in cisplatin-
resistant ovarian cancer [41]. 
Similarly, silencing of miR-130b, in cisplatin-resistant A2780 and paclitaxel-
resistant A2780 and SKOV3 cells, promote drug resistance through colony stimulating 
factor 1 (CSF1) targeting. MiR-130b silencing was inversely related to DNA methylation 
and resistance development. Thus, CSF1 knockdown is a potential treatment to re-
sensitize cells to chemotherapy and improve clinical outcomes [36]. Epigenetic silencing 
of BLU, a tumor suppressor gene, in paclitaxel-resistant ovarian tumor samples led to 
resistance development, and BLU methylation indicated a shorter progression-free and 
overall survival in patients. BLU methylation levels may be a promising prognostic 
biomarker in advanced serous ovarian carcinoma patients [42]. 
 
1.1.6 Epithelial-Mesenchymal Transition 
Paclitaxel-resistance in A2780 cells induces morphological changes consistent 
with epithelial-mesenchymal transition (EMT) and an increase in EMT-related 
biomarkers confirmed by RT-PCR. Activation of the PI3K/Akt pathway is vital to EMT; 
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thus, when PI3K was inhibited, paclitaxel sensitivity increased and cytoskeleton 
morphology shifted toward an epithelial phenotype [43]. In A2780 cells resistant to 
cisplatin, Snail and Slug, EMT transcription factors, contribute to resistance as evidenced 
by cell morphology changes, from spherical epithelial cells to spindle-like cells with 
formation of pseudopodia. A whole transcriptome microarray revealed overexpression 
of E-cadherin transcriptional repressors, Slug, Snail, TWIST2, and ZEB2, and 
downregulation of E-cadherin in A2780-cis cells compared to the parental A2780 line. 
Knockdown of Snail and Slug reversed the EMT phenotype and reduced resistance to 
cisplatin [44]. Snail, Slug, and TWIST upregulation were also linked to platinum 
resistance and EMT phenotypes in stage III-IV epithelial ovarian tumor biopsies. 
Activation of the TGF-β pathway led to activation of EMT, and relapse in 70% of patients 




TARGETED DELIVERY SYSTEMS TO COMBAT DRUG RESISTANCE IN OVARIAN CANCER 
 
2.1 Delivery Strategies for Overcoming Drug Resistance  
In order to combat different mechanisms of drug resistance development, a 
variety of therapeutics and delivery strategies have been studied to target and reverse 
chemoresistance in cancer cells. Currently, in ovarian cancer, the most common 
methods of reversal are treatment with siRNAs to manipulate the dysregulated genes 
and inhibitors to target the imbalance of efflux and influx in cells. Anti-resistance 
therapeutics aim to re-sensitize the cancer cells to chemotherapy drugs so further 
treatment can be administered to increase progression-free survival of cancer patients.  
In order to deliver siRNAs, inhibitors, and chemotherapeutic agents, alone or in 
combination to chemo-resistant cancer cells, many targeted delivery systems have been 
developed. Current methods include a variety of nanocarriers to increase the efficacy of 
chemotherapy drugs and other therapeutic agents while also decreasing negative side 
effects, like systemic toxicity. The nanocarriers are developed from polymers, lipids, 
peptides, and other inorganic molecules, as depicted in Figure 2.1. 
 The delivery systems used for combatting treatment in drug-resistant ovarian 
cancer are classified into two groups, single agent delivery or combination delivery. 
Single-agent delivery systems are used to increase the targeting and efficacy of one 
therapeutic agent. Typically, a drug carrier is used to increase cellular uptake by cancer 
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cells compared to free drug treatment and decrease off-target effects, limiting the 
damage to healthy cells. The goal of combination treatment is to maximize the 
synergistic ability of two compounds to increase anticancer effects while also decreasing 






Nanoparticles for single-agent use have already performed well in clinical trials. 
One of the most common, liposomal doxorubicin, is an FDA-approved chemotherapy 
drug and is widely used in cancer treatment. The benefit of the liposomal form of the 
drug is increased circulation time compared to free doxorubicin due to protection 
against destruction by the immune system [46]. Similar to this idea, many current 
studies seek to improve the efficacy of common chemotherapeutic agents through 
development of targeted therapies.  
 
2.1.1 Lipid 
 Lipid-based delivery systems are advantageous due to their drug loading 
versatility, utility for combination therapies, ability to modify surface characteristics, and 
decreased toxicity compared to free therapeutics. Drug loading in lipids, especially 
liposomes, is optimal because hydrophilic and hydrophobic drugs can both be loaded. 
The hydrophobic tails of lipids are sufficient environments for hydrophobic drugs to 
reside, while hydrophilic drugs can be loaded into the center of liposomes. In order to 
combat drug resistance in ovarian cancer cells, the versatility of lipid delivery systems 
can elicit greater anticancer effects through targeting activity of efflux transporters, 
cancer stem cells (CSCs), metabolism dysregulation, and hypoxic environments.  
 Increasing intracellular accumulation of therapeutics remains one of the main 
goals of nanoparticle delivery systems, thereby decreasing off-target toxicity and 
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increasing the efficacy of the delivered therapeutics. In drug-resistant ovarian cancer, 
increasing uptake of therapeutics is necessary to increase the concentration of drugs 
ultimately reaching the targeted tumor site. Solid lipid nanoparticles loaded with 
paclitaxel and doxorubicin have exhibited increased cellular uptake into A2780res and 
SKOV3TR drug-resistant ovarian cancer cells, increasing the anticancer effects of the 
treatment compared to free drug treatment alone [47,48].  
Increase in intracellular uptake has also been demonstrated through the use of 
surface-modified liposomes for targeting ovarian cancer cells. Folic acid is used to target 
folate receptors, which are overexpressed on the surface of ovarian cancer cells. One 
study showed paclitaxel-loaded nanoparticles decorated with folic acid demonstrated 
increased cellular uptake and inhibited growth and doubling time in SKOV/TAX cells 
compared to undecorated paclitaxel nanoparticles [49]. The addition of polyethylene 
glycol (PEG) to lipid nanoparticles also increases the stealth and uptake of the particles 
into drug-resistant SKOV3 ovarian cancer cells by evading efflux transporters [50]. 
Due to a relationship between CSC activity and aggressiveness of tumors, 
decreasing activity of CSCs has gained increasing popularity as a method to target drug 
resistance development in ovarian cancer cells. A novel, liposomal form of paclitaxel has 
been found to suppress CSC sub-populations, from drug-resistant ES-2 ovarian cancer 
cells, when delivered intraperitoneally compared to intravenously administering 
paclitaxel alone, as indicated by decreased levels of CSC-markers, CD44, CD24, and 
CD133 [51]. Metabolic reprogramming from glycolysis to oxidative phosphorylation was 
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also induced through reactivation of p53 in resistant ES-2 cells resulting in better control 
of tumor growth [51].  
The ability to deliver treatments in combination provides a promising method to 
synergistically enhance the efficacy of therapeutics, especially those used to treat drug-
resistance in ovarian cancer. Crosslinked multilamellar liposomes developed to deliver 
carboplatin and paclitaxel, two of the most common intravenous chemotherapeutics, 
were shown to increase anticancer effects in NCI/ADR-RES ovarian cancer cells in vitro 
and in OVCAR8 ovarian cancer xenograft mice models [52]. Also, in vitro studies showed 
decreased cancer stem cell activity in NCI/ADR-RES cells, where ALDH+ cells decreased 
from 57.3% in the untreated control to 30.2% in the resistant cells treated with the 
combination liposomes [52].  
Combination therapies have also been used to mediate resistance by avoiding 
efflux of chemotherapeutics by p-gp membrane transporters and hypoxia-induced 
resistance on ovarian cancer cells. Liposomes containing paclitaxel and tariquidar, a 
third-generation p-gp inhibitor, blocked proliferation and induced G2-M phase arrest in 
SKOV3-TR and HeyA8-MDR drug-resistant ovarian cancer cells in vitro. The combination 
liposomes reduced tumor weight to 16.9% from 43.2%, in mice xenografts with 
orthotopic HeyA8-MDR tumors compared to paclitaxel-only liposomes [53]. To address 
resistance related to hypoxia, liposomes containing doxorubicin and antisense 
oligonucleotides (ASO) targeting HIF-1α mRNA were delivered to A2780/AD 
doxorubicin-resistant ovarian cancer cells in vitro and athymic nu/nu mice with 
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A2780/AD subcutaneous tumors in vivo [54]. Confocal microscopy and in vivo 
fluorescence imaging identified intracellular localization of the combinatorial liposomes, 
and RT-PCR and IHC-staining showed decreased expression of HIF-1α when compared to 
free or liposomal doxorubicin without ASOs. Increased cell death signals were shown 
through expression of apoptotic proteins, BAX, CASP3, CASP9, and P53, as well as 
decreased expression of VEGF, identifying a decrease in tumor vascularization [54]. 
The various modifications of liposomal delivery of therapeutics in order to 
increase targeting, intracellular uptake, and efficacy of drug-resistant cancer treatments 
are promising in that the delivery systems can be modified to exploit the different 
mechanisms of resistance and overexpression of receptors in cancers on an individual 
basis. Personalized cancer treatment could lead to higher remission rates and lower 
incidence of drug resistance in secondary treatment. Liposomal therapeutic options 
show promise in future applications of targeted therapies as few treatments have 
reached clinical trials.  
 
2.1.2 Polymer 
 Polymer nanoparticles are the most common synthetic delivery systems utilized 
in targeted treatments for drug-resistant ovarian cancer. Similar to lipids, polymers 
possess the ability to increase intracellular accumulation of therapeutics, increase 
efficacy of treatments via surface-conjugated targeting moieties, deliver synergistic 
combination agents, and sustain the release of therapeutics. Increased accumulation 
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and efficacy of paclitaxel and cisplatin in drug-resistant A2780 ovarian cancer cells 
resulted from single-agent delivery in poly (n-butylcyanoacrylate) nanoparticles 
compared to free paclitaxel or cisplatin treatment [55,56]. 
 Similar to surface modifications in lipids, the addition of targeting moieties in 
polymer-based nanoparticles has been shown to increase uptake of therapeutics 
thereby increasing anticancer effects. Folate-targeted triblock copolymer nanoparticles 
delivered TLR4 siRNA and paclitaxel to drug-resistant SKOV3 ovarian cancer cells in vitro, 
to re-sensitize cells to paclitaxel and mediate TLR4-driven resistance [57]. Folate has also 
been used to increase uptake of paclitaxel-loaded PLGA nanoparticles [58]. In addition 
to folate, biotin is a common targeting ligand used for ovarian cancer due to its affinity 
for EGF receptors, which mediate resistance via the epithelial-mesenchymal transition. 
Biotinylated-PAMAM dendrimers exhibited a ten-fold increase in intracellular 
accumulation of cisplatin in A2780-CP70 cisplatin-resistant ovarian cancer cells 
compared to free cisplatin treatment alone [59]. Hyaluronic acid is an important 
targeting moiety for ovarian cancer cells as it targets CD44, a cancer stem cell and drug 
resistance marker. HA-targeted PEI/PEG nanoparticles were developed to deliver MDR1 
siRNA and paclitaxel to OVCAR8TR cells in vitro [60]. MDR1 siRNA knockdown increased 
sensitivity of cells to paclitaxel by decreasing p-gp activity and increased cellular uptake 
by targeting CD44, compared to untargeted nanoparticles [60].  
 Combinatorial delivery of anticancer therapeutics is an advantage of the 
versatility of polymer-based nanoparticle design. Like lipids, paclitaxel and p-gp inhibitor 
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molecules, tacrolimus and borneol, have been delivered in combination to elicit a 
greater anticancer effect than either of the drugs alone, by decreasing efflux and 
increasing intracellular accumulation of paclitaxel in A2780 paclitaxel-resistant ovarian 
cancer cells in vitro [61,62]. The combination of two molecular therapeutics was also 
demonstrated by co-encapsulation of doxorubicin and rhein in vitamin E-PEG 
nanomicelles and of paclitaxel and lonidamine in PCL-EGFR targeted NPs. In comparison 
to free drug treatment, both types of polymer nanoparticles exhibited increased tumor 
targeting and cytotoxic activity when studied in vitro on drug-resistant SKOV3 ovarian 
cancer cells [63,64]. Combinatorial delivery also includes simultaneous delivery of 
multiple siRNA, as demonstrated by the delivery of MDR1 and PKM2 siRNA in HA-
targeted PEI-PEG NPs to SKOV3TR ovarian cancer cells. The synergistic ability of the dual 
silencing of multidrug resistance protein and pyruvate kinase isoform 2 showed a 1.3 
fold decrease in IC50 value of paclitaxel when drug delivery followed siRNA delivery in 
SKOV3TR cells, but there was no significant difference in IC50 when delivered to wild-
type SKOV3 cells [65].  
 The most advantageous quality of polymer-based sustained release of 
therapeutics due to stimuli-responsive or biodegradable characteristics. Sustained 
release allows the drug to be exposed to the cancer cells for a longer period of time, 
which leads to increased efficacy of the therapy. pH-responsive polymer nanoparticles 
exploit the acidic environment of tumors in order to maintain a sustained release of 
therapeutics. Poloxamer 407 vitamin E-TPGS mixed micelles functionalized with folate 
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exhibited decreased efflux of doxorubicin in doxorubicin-resistant SKOV3 ovarian cancer 
cells, where accumulation increased 24% with the addition of poloxamer 407 and 264% 
with the addition of TPGS, when compared to efflux rates of untreated Dox-resistant 
SKOV3 cells [66]. The increased accumulation of doxorubicin led to an increase in 
doxorubicin binding to DNA, increasing cytotoxicity compared to free doxorubicin. 
 Biodegradable polymers, like polylactic acid (PLA), polyglycolic acid (PGA), or a 
combination of the two, PLGA, promote sustained release of therapeutics through 
degradation of the delivery systems. PLGA nanoparticles developed with a poly-
dopamine and PEG coating prevented rapid release and clearance of paclitaxel in a 
BR5FVB1-Akt murine ovarian cancer model [67]. Mice treated with the PLGA NPs 
showed an 8-fold increase in paclitaxel concentration in the peritoneal cavity than mice 
treated with free paclitaxel, while the systemic circulation of paclitaxel was three times 
higher in the free paclitaxel treatment than the nanoparticle treatment [67]. PLGA 
nanoparticles were shown to sustain release of diphtheria toxin-subunit A suicide genes 
in chemo-resistant ovarian tumor-bearing SCID mice, inhibiting tumor growth [68]. 
Chitosan-coated PLA NPs mediated release of p62 siRNA, β5 plasmid, and cisplatin, in 
C13 cisplatin-resistant ovarian cancer cells in vitro, as demonstrated by a 26% decrease 
in IC50 of cisplatin, compared to only 15.2% with delivery of sP62 alone or 8% with pβ5 
[69]. 
 Overall, polymer nanoparticles possess many desirable qualities for targeted 
therapy options in the reversal and treatment of drug-resistant ovarian cancer. While 
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qualities like sustained release and specific stimuli response favor polymer systems over 
lipids, most of the concepts of the two types of delivery systems remain similar. Thus, 
the addition of targeting ligands, the potential to co-encapsulate therapeutics, and the 
increase in intracellular accumulation and cytotoxicity are all important to developing a 
successful targeted therapy for treatment of drug resistance in ovarian cancer.  
 
2.1.3 Inorganic 
 Beyond lipids and polymers, other nanoparticles have become popular in 
studying reversal of drug resistance in ovarian cancer, specifically, silica and metal 
nanoparticles. Mesoporous silica nanoparticles (MSNs) are desirable for the delivery of 
siRNA specifically to perinuclear targets in vitro and in vivo. MSNs have been utilized to 
deliver and knockdown TWIST siRNA to decrease tumor burden in mice and target the 
epithelial-mesenchymal transition when treated concurrently with cisplatin compared 
to cisplatin alone [70]. Combination therapy has been attempted with MSNs as well, 
delivering doxorubicin and Bcl-2 siRNA to control and decrease apoptosis-related 
resistance. The off-target release of doxorubicin was minimal and the intracellular 
localization of the agents increased indicating successful management of resistance and 
increased efficacy of doxorubicin [71].  
 Metal nanoparticles, such as iron oxide, silver, and copper, are modified with 
organic materials and loaded with therapeutic agents to treat drug-resistant ovarian 
cancer. Iron-oxide nanoparticles as delivery systems for doxorubicin have been shown 
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to sustain slow release of DOX at slightly acidic pHs and avoid drug efflux pumps [72]. In 
addition, release of doxorubicin from mesoporous iron-oxide nanoparticles has also 
been studied for combination therapy with hyperthermia, where DOX burst release 
occurs upon magnetic heating [73]. Lycopene-reduced graphene oxide-silver 
nanoparticles were developed for co-delivery with trichostatin A. The combined effects 
of these two agents decreased cell viability in a dose-dependent manner through an 
increase in apoptosis due to DNA fragmentation and double strand dysfunction [74]. 
Similarly, phosphorous dendrimers were modified with copper to target BAX pathways. 
The copper-phosphorus structures increased apoptosis by increasing activation of the 
BAX signaling pathway [75]. The benefit of using a metal nanoparticle is that therapeutic 
agents may not be needed as some metals elicit anticancer effects alone.  
 
2.1.4 Theranostic 
 Lastly, some delivery systems aim to improve treatment and diagnostic abilities 
in a single therapy by personalization of therapy to meet patient’s varying needs. These 
methods are designated as theranostic approaches in which nanoemulsions of 
chemotherapeutic drugs are delivered and imaged to predict the success of the therapy 
in different patients [76]. Nanoemulsions load platinum drugs and doxorubicin, and they 
are functionalized with folate in order to increase on-target localization of the particles. 
Targeted nanoemulsions have demonstrated increased cytotoxicity due to efficient 




2.2 Current Clinical Trials 
 Overall, the versatility of nanoparticle delivery systems in the reversal and 
treatment of drug-resistant ovarian cancer seems to be a promising quality; however, 
targeted therapy research is cutting-edge and there has yet to be much translation from 
the research setting into the clinical setting. Clinical trials for ovarian cancer currently 
focus on options improving traditional chemotherapy drugs to treat recurrent or 
resistant cancer through modifications in dosing regimens, differing combinations of 
drugs, and changing the method of delivery of the drugs, as laid out in Table 2.1. The 
more recent targeted therapies have yet to become popular in clinical trials due to poor 
translation of treatments, but a few have been tested as second, third, or last lines of 
therapy.   
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Table 2.1.Clinical Trials for Ovarian Cancer Treatment. Recent clinical trials for ovarian cancer characteristics and 
phases, with accompanying results. 
 
Drug(s) In trial Phase Delivery Method/Regimen Drug mechanism(s) 
Paclitaxel I Novel liposomal platform[79]  Paclitaxel stabilizes microtubules during mitosis and 




I IV pertuzumab every 3 weeks 
with either topotecan every 3 
weeks or paclitaxel weekly[80] 
Pertuzumab inhibits ligand-dependent HER2-HER3 
dimerization and reduces signaling through PI3K 
pathway; Topotecan inhibits topoisomerases to cause 
double strand DNA breakage and cell death 
Paclitaxel and 
carboplatin 
II Cremophor-free polymeric 
micelles of paclitaxel IV with 
carboplatin every 3 weeks[81] 
Carboplatin inhibits DNA synthesis by causing intra- 
and inter-strand crosslinking in DNA 
Temsirolimus II Weekly IV infusions[82] Temsirolimus inhibits mTOR leading to cell cycle 
arrest in the G1 phase and inhibiting tumor 
angiogenesis 
Olaparib II Oral capsules[83] Olaparib inhibits PARP enzymes and DNA repair 
Pazopanib II Daily pazopanib with or 
without weekly paclitaxel[84] 




II Cremophor-free nanoparticle 
of albumin-stabilized paclitaxel 
IV[85] 
Paclitaxel stabilizes microtubules during mitosis and 
leads to mitotic arrest 
Paclitaxel II Lipid core nanoparticles weekly 
IV infusion[86] 
Paclitaxel stabilizes microtubules during mitosis and 




II Paclitaxel and carboplatin IV 
infusions with or without twice 
daily sorafenib orally[87] 
Sorafenib inhibits tyrosine kinases in Raf/MEK/Erk 
pathways and induces autophagy 
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2.3 Conclusion and Future Steps 
  Due to the aggressive malignancy, the limited early diagnostics, and the potential 
of drug resistance in ovarian cancer, there is a significant need for increased efficacy and 
specificity in treatment. Without much-needed advancements in diagnostic methods 
and patient compliance for screenings, the only option to limit the negative effects of 
ovarian cancer is to improve treatment success. Reversal of drug resistance is currently 
at the forefront of ovarian cancer research, showing promising results in vitro and in 
vivo. Numerous inhibitors and siRNA have been successful in re-sensitizing cells to 
chemotherapy, including P-gp inhibitors, PARP inhibitors, and siRNA to modify 
expression in signaling pathways important for cancer proliferation and progression. The 
success of these inhibitors, while promising, remains low due to the complexity and 
interdependence of mechanisms protecting the cells from chemotherapeutic agents.  
Nanoparticles have become an increasingly popular option to deliver drug 
resistance reversal agents in combination with chemotherapeutic agents to achieve 
greater anti-cancer effects without increasing the danger of therapy to patients. 
Nanoparticles can be developed from lipids, polymers, inorganic materials, or a 
combination of the molecules in order to decrease toxicity of the drugs being delivered. 
However, the significance of nanoparticle delivery systems actually lies in the ability to 
modify particles to increase targeting specificity, increase intracellular accumulation, 
and decrease premature clearance of the drugs before reaching the targeted area. 
Translation from in vivo studies to clinical trials has been one of the largest obstacles in 
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producing new treatment options for current ovarian cancer patients. Recently, a few 
nanoparticle-based therapies have made their way into clinical trials, with hopes that as 
more research is done on targeted therapies in ovarian cancer models, the number of 

















Ovarian cancer is the deadliest gynecological malignancy and the fifth leading 
cause of cancer-related death overall. Around 60% of ovarian cancer cases are 
diagnosed in the distant stages, where the survival rate is only 21-29% [1].  The 
aggressiveness of the disease lies in the high rates of recurrence and the development 
of drug resistance after initial treatment. 70% of ovarian cancer patients will experience 
a recurrence of their cancer [2], where the development of resistance to prior 
chemotherapy regimens creates difficulty in determining an appropriate second-line 
regimen. Currently, the standard treatment of a recurrence is to choose a 
chemotherapy drug that has not shown cross-resistance with the first regimen.  
However, some tumors will develop resistance to many chemotherapy drugs. Thus, 
there is a significant need for therapies to increase the survival rate of drug-resistant 
ovarian cancer.  
The objective of this research is to identify potential gene targets involved in the 
development of paclitaxel-resistance in ovarian cancer cells. Initial treatment of ovarian 
cancer includes a regimen consisting of cycles of a platinum-based DNA-alkylating agent, 
carboplatin or cisplatin, and paclitaxel, a microtubule stabilization agent [88]. Therefore, 
the effectiveness of secondary treatments containing paclitaxel decreases if paclitaxel-
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resistance has developed. The overall goal of this research is to synthesize and 
characterize cholesterol- and cholesteryl hemisuccinate (CHEMS)-based liposomal 
combination delivery systems for siRNAs, specific to gene targets with identified 
involvement in drug resistance in ovarian cancer cells, and paclitaxel to synergistically 
increase the efficacy of paclitaxel in drug-resistant ovarian cancer.  
Through completion of the following aims, I will collect the data necessary to 
identify potential gene targets involved in the development of paclitaxel-resistance, as 
well as synthesize and characterize two liposomal carriers with the ability to encapsulate 
and deliver paclitaxel and siRNAs to drug-resistant ovarian cancer cells. Comparison of 
the two liposomal delivery systems will determine the potential of substituting CHEMS 
for cholesterol to incorporate a pH-sensitive compound without compromising the 
loading and delivery ability of the liposomes.  
Aim 1: Identify gene targets involved in the development of paclitaxel-resistance in 
ovarian cancer cells with a siRNA array. We will design a custom array of siRNAs specific 
to genes involved in apoptosis, the cell cycle, and drug resistance development in 
cancer. Through siRNA transfection with the custom array followed by paclitaxel 
treatment, we will identify the siRNAs responsible for the greatest anticancer effect in 
paclitaxel-resistant ovarian cancer cells. We hypothesize that the siRNAs which 
demonstrate the greatest anticancer effect in combination with paclitaxel when 
compared to treatment with paclitaxel alone, will correlate to genes involved in the 
development of resistance in ovarian cancer cells.  
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Aim 2: Synthesize and characterize cholesterol- and cholesteryl hemisucciante-based 
liposomal carriers, and compare their ability to encapsulate and deliver both 
paclitaxel and siRNA to drug-resistant ovarian cancer cells.  We will synthesize cationic, 
cholesterol-based liposomes and cholesteryl hemisuccinate-based liposomes and 
examine the size, surface charge, encapsulation efficiency, siRNA binding, stability, and 
cellular uptake of the liposomes. We hypothesize that both types of liposomes will be 
positively charged and uniform in size. We also hypothesize that the liposomes will be 
stable when paclitaxel is loaded in the hydrophobic region of the lipid bilayer and 
negatively-charged siRNA is bound to the cationic lipid components. We believe that 
cellular uptake will be achieved through endocytosis of the cationic liposomes. We 
believe that cholesteryl hemisuccinate can be substituted for cholesterol in the 
synthesis of the liposomes without compromising the encapsulation ability or stability of 
the liposomes.  
3.2 Approach 
Aim 1:  
After determining the IC50 value of paclitaxel in OVCAR3 and OVCAR3-TR, wild-
type and drug-resistant ovarian cancer cells, we will evaluate the viability of OVCAR3-TR 
cells after transfection with the custom siRNA array and 15 nM paclitaxel treatment 
using an MTS assay. Gene targets will be chosen based on the siRNAs demonstrating the 
greatest anticancer effects compared to treatment with paclitaxel alone. These chosen 
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siRNAs will be used as therapeutics bound to the liposomes to re-sensitize cells when 
delivered in combination with paclitaxel.  
Aim 2: 
After identification of the gene targets, we will synthesize and characterize the 
liposomes using dynamic light scattering to determine size and polydispersity index of 
the particles, and micro-electrophoresis with phase analysis light scattering to find the 
zeta potential. Then, we will examine the encapsulation efficiency of paclitaxel in the 
liposomes when loaded with 2.5 µg/mL of paclitaxel. The amount of drug loaded will be 
determined with high-performance liquid chromatography (HPLC). 
After determining paclitaxel loading, we will evaluate the binding/loading of 
siRNA to the liposomes to quantify the amount of siRNA available for knockdown upon 
delivery into the drug-resistant cells. Liposomes loaded with fluorescent non-targeting 
siRNAs allow the use of fluorescence spectrophotometry to determine the amount of 
siRNA bound to liposomes. siRNA binding will be further studied with a gel shift assay to 
ensure binding and protection of siRNAs and stability of loaded liposomes.  
Cellular uptake will be visualized using immunofluorescence, fluorescent labeling 
of early endosomes, nuclear counterstaining, and fluorescent siRNA and Nile Red loaded 
liposomes. OVCAR3-TR cells treated with 100 µM of liposomes will be fixed at 2 hour 
time points, and fluorescence microscopy will be used to evaluate the intracellular 
localization of the liposomes.  
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CHAPTER FOUR 
IDENTIFYING GENE TARGETS IN THE DEVELOPMENT OF PACLITAXEL RESISTANCE IN 
OVARIAN CANCER CELLS 
Due to lack of early symptoms, a majority of ovarian cancer diagnoses occur in 
the distant stages, leading to a low five-year survival rate of about 21-29% [1]. Low 
survival rates are believed to be linked to recurrence of cancer and development of drug 
resistance after initial treatment, which involves tumor resection surgery and a 
chemotherapy regimen, usually including cisplatin or carboplatin, both platinum-based 
DNA-alkylating drugs, and paclitaxel, a microtubule inhibitor [6,88]. Without advances in 
current diagnostic methods, there is a significant need to find a therapy that is effective 
on drug-resistant ovarian cancer.  
The underlying intracellular mechanisms responsible for resistance are complex 
and intertwined, making it difficult to treat the disease by targeting only one 
mechanism. Thus, combination therapy has been heavily researched as a treatment 
option for drug-resistant cancer. Combination therapies allow two or more therapeutics 
to be delivered simultaneously, with the goal of synergistically increasing the efficacy of 
either treatment alone [89,90]. Therapeutics in combination therapies include 
chemotherapeutics, inhibitor molecules, and siRNAs. Controlling expression of genes 
that are believed to be involved in the development of drug resistance with siRNAs 
could be vital in treating recurrent cancer and re-sensitizing cancer cells to cisplatin, 
carboplatin, and paclitaxel [91,92]. siRNAs delivered into the cell form an RNA-induced 
33 
silencing complex with proteins and specifically bind to target mRNA, interrupting 
translation and degrading the mRNA [93]. siRNAs can target the various pathways 
involved in the development of drug-resistance in ovarian cancer by knocking down 
overexpressed genes coding for p-gp membrane transporters, apoptosis, autophagy, 
cancer stem cells, epigenetics, and the epithelial-mesenchymal transition. Combination 
therapies can elicit increased anticancer effects by using siRNAs or inhibitors to re-
sensitize cells to chemotherapy drugs and treat the cells simultanously with delivered 
chemotherapeutics.  
Here, a custom siRNA array of gene targets involved in apoptosis and the cell 
cycle was designed in order to identify genes that may be involved in the development 
of drug resistance in ovarian cancer cells. The anticancer effect of siRNA transfection 
followed by paclitaxel treatment was studied in OVCAR3-TR cells. We found five siRNAs 
had significantly greater anticancer effects compared to treatment with paclitaxel alone. 
4.1 MATERIALS AND METHODS 
4.1.1 Materials 
The custom siRNA array was designed by including siRNAs from apoptosis and 
cell cycle gene libraries, as well as siRNAs recently shown in literature to play a role in 
development of drug resistance, and purchased from Dharmacon (Lafayette, CO). 
Transfection supplies including 5x siRNA buffer, GAPDH siRNA, and Non-targeting #5 
siRNA were also purchased from Dharmacon. Lipofectamine RNAiMAX and OPTIMEM 
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media were both acquired from ThermoFisher Scientific (Waltham, MA) as well as cell 
culture reagents, fetal bovine serum (FBS), penicillin/streptomycin, and trypsin. The 
OVCAR3 cell line was obtained from ATCC (Manassas, VA) and the OVCAR3-TR cell line 
was a generous donation from Dr. George Duran at Stanford University. McCoy’s 5A 
modified media, phosphate-buffered saline (PBS), RNA grade water, and dimethyl 
sulfoxide (DMSO) were purchased from Fisher Scientific (Pittsburgh, PA).  Paclitaxel was 
obtained from LC Laboratories (Woburn, MA). Thiazolyl Blue Tetrazolium Bromide 
(TBTB) was purchased from Sigma-Aldrich (St. Louis, MO). Cell Titer One Aqueous 
Solution Cell Proliferation Assay was acquired from Promega (Madison, WI).  
4.1.2 Cell Culture 
The human ovarian carcinoma cell lines OVCAR3 and OVCAR3-TR were cultured 
in McCoy’s 5A Modified Medium with 10% FBS and 1% antibiotic (100 IiU/mL penicillin 
and 100 µg/mL streptomycin). Both cell lines were cultured in an incubator at 37°C with 
5% CO2. 
4.1.3 IC50 Studies 
The half maximal inhibitory concentration (IC50) value of paclitaxel in OVCAR3 
and OVCAR3-TR ovarian cancer cell lines was determined to find the level of resistance 
in OVCAR-TR cells. Both cell lines were seeded at 35,000 cells/well in two 24-well plates 
and allowed to attach overnight. Paclitaxel dissolved in DMSO was added to the cells 
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and allowed to incubate in media containing 10% FBS with a final paclitaxel 
concentration ranging from 0-10 nM in the OVCAR3 cells and 0-100 nM in the OVCAR3-
TR cells for 24 hours. After 24 hours, the cells were washed with PBS three times to 
ensure the removal of drug and media was replaced for another 48-hour incubation 
period. After a total of 72 hours post-treatment, the cytotoxicity of paclitaxel was 
examined using an MTT assay. The media was removed from the cells and Thiazolyl Blue 
Tetrazolium Bromide was dissolved in PBS at a concentration of 2 mg/mL and added to 
the cells for a final concentration of 1 mg/mL. The cells were then incubated with TBTB 
for 4 hours at 37°C. After incubation, the TBTB was aspirated from the cells and 
formazan crystals were solubilized with 500 μL of DMSO in each well. The absorbance of 
each well was measured at a wavelength of 540 nm on a Biotek Synergy plate reader 
(Winooski, VT). Cell viability was normalized to untreated cells and calculated with the 
equation below: 
Cell Viability (%)= (
Absorbance 540 (sample)
Absorbance 540 (control)
 ) x 100. 
The ratio of IC50 values in the resistant OVCAR3-TR cells compared to the wild-type 
OVCAR3 cells was calculated to determine the level of resistance.  
4.1.4 siRNA Array for Gene Target Identification 
A custom siRNA array was developed by identifying genes involved in apoptosis 
and the cell cycle, as well as genes recently found to be involved in drug resistance 
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development, specifically in ovarian cancer. After the IC50 values were determined, an 
optimal paclitaxel treatment concentration (15 nM) was found through MTT studies for 
the siRNA array experiment. OVCAR3-TR cells were seeded at 7,000 cells per well in a 
96-well plate and incubated overnight to allow for attachment. The cells were
transfected with 50 nM siRNA from the custom array and from controls and incubated 
at 37° C for 24 hours. Five controls were used for the array, GAPDH siRNA, a positive 
targeting control, Non-targeting #5 siRNA, a non-targeting control, lipofectamine only, 
free paclitaxel only, and an untreated control. 24 hours post-transfection, the 
transfection media was removed and the cells were treated with 15 nM paclitaxel and 
incubated for another 24 hours.  
At the 48-hour time point, an MTS cell proliferation assay was performed using 
the Cell Titer 96 Aqueous One Solution Cell Proliferation Assay. The cells were incubated 
for 2 hours at 37°C with 20 μL of the Cell Titer reagent.  After incubation, absorbance 
was measured using a Biotek Synergy plate reader (Winooski, VT) at an absorbance of 
490 nm. Absorbance values were used to calculate cell viability compared to untreated 
OVCAR3-TR cells using the equation: 
Cell Viability (%)= (
Absorbance 490 (sample)
Absorbance 490 (control)
 ) x 100. 
The anticancer effects were determined by comparing the viability associated with each 
siRNA in the array to the viability of cells treated with free paclitaxel only.  
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Statistical analysis was performed on the viability data from the array to 
determine significant anticancer effects. Gene targets were chosen based on the highest 
mean anticancer effects as demonstrated by the lowest viability values.  
4.1.5 Statistical Analysis 
Quantitative data were presented as mean ± SEM of three independent 
experiments. Statistical analysis was performed using a Student's t-test or one-way 
ANOVA, with *P < 0.05, **P < 0.01, and ***P < 0.001, and a value of P < 0.05 was 
considered statistically significant.  
4.2 RESULTS 
4.2.1 IC50 Studies 
Drug-resistance is identified by an increase in half maximal inhibitory 
concentration of a drug on cells. The results comparing anticancer activity of paclitaxel 
in OVCAR3 cells to resistant OVCAR3-TR ovarian cancer cells indicated an increase in 
IC50 value of paclitaxel in OVCAR3-TR cells. In the OVCAR3 cell line, the IC50 value of 
paclitaxel was 4.29 ± 0.12 nM. The resistant OVCAR3-TR cells showed a ten-fold increase 
in paclitaxel IC50 value, 43.10 ± 2.41 nM, indicating a more resistant phenotype toward 
paclitaxel than the OVCAR3 cells.  
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4.2.2 Identification of Gene Targets 
A custom siRNA array (Fig. 4.1) was used to identify gene targets that may be 
involved in the development of drug resistance in ovarian cancer. From the anticancer 
effects determined via viability data, seven siRNAs demonstrated higher anticancer 
effects than paclitaxel treatment alone in OVCAR3-TR cells in vitro. Out of the seven 
siRNAs identified, five siRNAs demonstrated significantly higher anticancer activity than 
paclitaxel treatment alone, including, CASP8AP2, PAK2, ABCB1, JAK2, and CFLAR (Fig. 
4.2A-B). The three siRNAs the results in the lowest viability in combination with 
paclitaxel compared to treatment with paclitaxel alone were chosen as gene targets. 
ABCB1, which codes for ATP-binding cassette transporters and manages efflux of 
molecules out of cells, demonstrated the third lowest viability at 49%. JAK2, Janus 
kinase 2, which plays a role in signaling cell growth, exhibited the second lowest viability 
at 34%. The lowest viability overall, 29%, was due to silencing CFLAR, an apoptosis 
regulator protein that inhibits caspase-8 cleavage, thereby inhibiting apoptosis.  
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CHAPTER 5  
SYNTHESIS AND CHARACTERIZATION OF COMBINATION LIPOSOMES FOR TREATMENT 
OF DRUG-RESISTANT OVARIAN CANCER 
Liposomes are multifunctional nanoparticles and allow for loading of hydrophilic 
and hydrophobic chemotherapeutics, singularly or simultaneously, for delivery to 
targeted cancer cells.  Liposomal formulations of chemotherapy drugs decrease 
hypersensitivity and off-target toxicity of chemotherapeutics delivered systemically. By 
encapsulating paclitaxel, a poorly water-soluble drug, in lipids, the goal is to decrease 
hypersensitivity and adverse effects due to polyoxyl-35 castor oil, used as a solubilizing 
vehicle to mediate intravenous delivery of the hydrophobic drug [94]. Many liposomal 
formulations of paclitaxel have been through clinical trials in recent years and are 
beginning to gain clinical relevance as treatments for patients with ovarian cancer [95].  
Liposomes are not only useful for eliminating the need for harsh solvents or 
vehicles needed for delivery of poorly water-soluble drugs, but also for their therapeutic 
loading versatility. Liposomes contain a region where phospholipid tails overlap and 
create a hydrophobic shell within the membrane bilayer, allowing for hydrophobic 
molecules to be loaded and protected inside the membrane. The core of liposomes, 
lined by the hydrophilic heads of phospholipids, creates a suitable environment for 
loading hydrophilic drugs. Thus, liposomes possess the ability to co-load both 
hydrophobic and hydrophilic drugs, a characteristic that can be exploited for increasing 
41 
the efficacy of chemotherapeutics, especially in difficult to treat cancers [52]. In addition 
to co-loading drugs, liposomes also can load nucleic acid therapeutics, including plasmid 
DNA, siRNA, and antisense oligonucleotides, through electrostatic interactions with 
cationic lipids, to regulate expression of cancer-related genes [96]. 
The benefits of combination delivery of therapeutics can be further improved by 
modifying liposomes with surface ligands, antibodies, and stealth components [50,97]. 
Modifications can assist in targeting and reversing drug-resistance mechanisms in 
ovarian cancer. Inhibition of drug resistance mechanisms combined with chemotherapy 
treatment have shown increased anticancer effects in drug-resistant ovarian cancer 
models compared to chemotherapy alone [98].  
To address drug resistance in ovarian cancer, we synthesized cationic, 
cholesterol- and cholesteryl hemisuccinate-based liposomes in order to deliver 
paclitaxel in combination with siRNA targeting genes involved in the development of 
drug resistance. The liposomes were designed to bind negatively-charged siRNA to 
cationic lipid components and load hydrophobic paclitaxel into the membrane bilayer. 
Characterization based on size, polydispersity index, and zeta-potential confirmed the 
formation of cationic liposomes. Efficient loading of paclitaxel and binding of siRNA into 
the liposomes as well as stability of the loaded liposomes were all demonstrated. 
Quantification of siRNA in CHEMS-LPs demonstrated lower concentrations than CHOL-
LPs in the fluorescence study, however similar siRNA binding was shown in the gel shift 
assay. Further analysis is needed to determine the loading potential of the CHEMS-LPs. 
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Cholesterol-based liposomes mediated cellular uptake of Nile Red and fluorescent non-
targeting #5 siRNA and CHEMS-LPs mediated uptake of fluorescent non-targeting #5 
siRNA into OVCAR3-TR drug-resistant ovarian cancer cells. 
5.1 MATERIALS AND METHODS 
5.1.1 Materials 
All lipid components, DOTAP, DPPC, and DSPE-PEG(2000), a mini hand extruder, 
and 0.2 µm polycarbonate membranes were purchased from Avanti Polar Lipids, Inc. 
(Alabaster, AL). Cholesterol, cholesteryl hemisuccinate, Nile Red, and chloroform were 
obtained from Sigma Aldrich (St. Louis, MO). Methanol, glucose, and acetonitrile were 
purchased from VWR (Radnor, PA). Paclitaxel was acquired from LC Laboratories 
(Woburn, MA). Fluorescent non-targeting #5 siRNA and non-targeting #5 siRNA were 
obtained from Dharmacon (Lafayette, CO). Electrophoresis materials including agarose, 
TAE buffer, ethidium bromide, Ambion PUC19 RNA Ladder, and agarose loading dye 
were purchased from Fisher Scientific (Pittsburgh, PA). Paraformaldehyde and Triton X-
100 were also purchased from Fisher Scientific. NucBlue ReadyProbes stain and Alexa-
488 Anti-rabbit secondary antibody were acquired from ThermoFisher Scientific 
(Waltham, MA). EEA1 rabbit monoclonal antibody was purchased from Cell Signaling 
Technology (Danvers, MA). 
5.1.2 Cell Culture 
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The human ovarian carcinoma cell line OVCAR3-TR was cultured in McCoy’s 5A 
Modified Medium with 10% fetal bovine serum (FBS), and 1% antibiotic 
(100iU/mLpenicillin/100ug/mL streptomycin). The cell line was grown in an incubator at 
37°C with 5% CO2. 
5.1.3 Liposome Synthesis 
Cationic liposomes were formed by dissolving lipids at a 25:40:30:4 molar ratio 
(DOTAP:DPPC:Cholesterol (or CHEMS):DSPE-PEG2000) in a 3:1 (v/v) mixture of 
chloroform and methanol as previously described [99]. The solvent was evaporated at 
40° C for 20 minutes and then the lipid film was allowed to vacuum dry for 2 hours to 
ensure complete removal of solvent. Fluorescent non-targeting #5 siRNA was added to 
RNA grade water with 5% glucose (w/v) and used to rehydrate the lipid film. The 
mixture was then sonicated in an ultrasonic bath for 20 minutes, followed by extrusion 
through a 0.2 µm filter membrane in a mini-hand extruder. After extrusion, the 
liposomes were diluted to the desired working concentrations and stored at 4°C. The 
same process was used to form liposomes containing cholesteryl hemisuccinate in place 
of cholesterol.  
5.1.4 Characterization of Liposomes 
Size and polydispersity index of the liposomes at a concentration of 5 mM was 
determined using Dynamic Light Scattering, while surface charge was determined via 
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micro-electrophoresis and phase analysis light scattering (M3-PALS) using a Zetasizer 
Nano ZS (Malvern Instruments, Malvern, UK). The Zetasizer was maintained at a 
temperature of 25°C while obtaining measurements. A refractive index of 1.45, an 
absorbance value of 0.001, and an angle of 173° was used to collect the intensity of 
scattered light due to the nanoparticles. Intensity-based size distribution plots were 
generated based on twelve separate measurements.  
5.1.5 Liposomal Loading Efficiency of Paclitaxel 
To release encapsulated paclitaxel from liposomes, liposomes were disrupted in 
methanol by centrifuging at 13,000 rpm for 20 minutes prior to HPLC analysis. Loading 
of paclitaxel into the liposomes was determined using an HPLC system consisting of a 
Waters Model 2707 Autosampler connected to a 1515 Isocratic HPLC Pump (Waters, 
Inc., Milford, MA). Samples of 50 µL were injected into a Waters Symmetry C18 (4.6 x 75 
mm, 3.5µm) column, with a gradient flow of water and acetonitrile beginning at 66:34 
(v/v) at a flow rate of 0.6 mL/min. The UV detector was set to 227 nm. The loading 
efficiency was determined by comparing encapsulated paclitaxel to the initial amount of 
paclitaxel dissolved with the lipids using the equation: 
Loading Efficiency (%) = (
Amount of drug detected
Amount of drug initially loaded
) × 100 
5.1.6 siRNA Binding and Stability in Liposomes 
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Agarose gel electrophoresis was performed to determine the binding and 
protection of siRNAs in the liposomes. Intact and disrupted liposome samples were 
loaded into a 2% agarose gel in TAE buffer and ran for 60 minutes at 100V. The gel was 
stained with ethidium bromide and imaged with a UV illuminator.  
Binding of siRNA to liposomes can be estimated by utilizing fluorescent siRNA 
and measuring the intensity of fluorescence when bound to liposomes. Fluorescence 
spectroscopy was performed in a Synergy Biotek plate reader (Winooski, VT) to examine 
the binding of siRNAs to the liposomes. Serial fluorescent siRNA dilutions were used to 
create a standard curve. Liposome solutions, including both 5 mM and 500 mM stocks, 
were used as samples and their fluorescence intensities were fit to the standard curve 
to determine the amount of siRNA bound. Liposome samples disrupted with 0.1% Triton 
X-100 were also used to examine the siRNA fluorescence intensity without interference
from the stable liposomes. Binding efficiency was calculated as: 
Binding Efficiency (%)= (
Amount of siRNA detected
Amount of siRNA initially added
) ×100 
5.1.7 Cellular Uptake of Liposomes 
Cellular uptake and intracellular accumulation of cholesterol-containing 
liposomes loaded with fluorescent non-targeting #5 siRNA and Nile Red were visualized 
using fluorescence microscopy. OVCAR3-TR cells were seeded at 35,000 cells per well in 
24-well plates and incubated to allow attachment overnight. The cells were treated with
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liposomes at a final concentration of 50 µM and incubated for 4 or 8 hours. At 4 and 8 
hours, the cells were stained with NucBlue ReadyProbes nuclear stain and imaged using 
an EVOS FL Cell Imaging System (ThermoFisher Scientific, Waltham, MA).  
Immunofluorescence assays were performed on OVCAR3-TR cells treated with 
cholesterol- and CHEMS-containing liposomes loaded with fluorescent non-targeting #5 
siRNA and paclitaxel. OVCAR3-TR cells were seeded at 35,000 cells per chamber on 8-
chamber collagen I-coated culture slides and incubated overnight for attachment. The 
cells were then treated with 50 µM liposomes containing cholesterol or CHEMS and 
incubated for 2 hours. OVCAR3-TR cells were fixed with 4% paraformaldehyde and 
permeabilized with 0.1% Triton X-100 in PBS. The cells were incubated at 4°C overnight 
with primary EEA1 antibody solution. Following incubation, cells were washed three 
times using PBS and incubated with Alexa Fluor 488-conjugated secondary antibody 
solution. Nuclear material was counterstained with mounting media containing DAPI. 
Fluorescence microscopy was used to visualize cellular uptake and intracellular 
accumulation of the liposomes.  
5.1.8 Statistical Analysis 
Quantitative data were presented as mean ± SEM of three or more independent 
experiments. Statistical analysis was performed using a Student's t-test. 
5.2 RESULTS 
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5.2.1 Characterization of Liposomes 
Two formulations of liposomes were synthesized using the same lipid film 
hydration method to create liposomes containing cholesterol (CHOL-LPs) and liposomes 
containing cholesteryl hemisuccinate (CHEMS-LPs) (Fig 5.1). After synthesis, the two 
types of liposomes were characterized by size, polydispersity index (PDI), and surface 
charge using DLS and M3-PALS at a concentration of 5 mM of liposomes. The mean 
particle size of the CHOL-LPs was 114.9 ± 10.35 nm, while the mean size of the CHEMS-
LPs was slightly lower at 91.29 ± 7.66 nm (Fig. 5.2A-B). The PDI of the CHOL-LPs, 0.252, 
was also higher than that of the CHEMS-LPs, 0.214 (Fig. 5.2C). Both values for PDI 
indicated monodisperse liposomes in solution with minimal aggregation. The mean zeta-
potentials of the CHOL-LPs and CHEMS-LPs, +27.6 ± 1.79 mV and +23.2 ± 1.56 mV 
respectively (Fig. 5.2C), were positive due to the cationic lipid component DOTAP and 
the ability of CHEMS to be protonated in aqueous solution. Both liposome formulations 
resulted in uniformly-sized, monodisperse, positively charged particles.  
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5.2.2 Efficient Loading of Paclitaxel into Liposomes 
In order to further compare the CHOL-LPs and CHEMS-LPs, the loading efficiency 
of paclitaxel in the liposomes was analyzed. Paclitaxel was dissolved with the lipids and 
rehydrated to form liposomes with a final drug concentration of 2.5 µg/mL. HPLC 
analysis was used to determine the amount of paclitaxel loaded into each type of 
liposomes, and the loading efficiencies of both types of liposomes were calculated. The 
CHOL-LPs exhibited a loading efficiency of 80.4%, while the CHEMS-LPs loaded with an 
efficiency of 79.3% (Table 5.1). Overall, the CHOL-LPs and CHEMS-LPs were comparable 
in their ability to load paclitaxel.  
5.2.3 Binding and Protection of siRNA in Liposomes 
A gel shift assay was performed to examine the siRNA binding capabilities of the 
CHOL-LPs and CHEMS-LPs. Samples of each liposome at concentrations of 5 mM and 
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500 mM were examined. siRNA content was also examined after disruption with 0.1% 
Triton X-100 in order to validate binding of siRNAs in liposomes. Intact and disrupted 
liposomes at a concentration of 5 mM showed no stained siRNA, likely due to the siRNA 
concentration being too dilute. Intact 500 mM CHOL-LPs and CHEMS-LPs stained for 
siRNA inside of the wells, while both disrupted 500 mM liposome samples appeared 
around the same area of the gel as free siRNA (Fig 5.3). Staining near the well in Lane 10 
indicates remaining siRNA bound to liposome components. The disrupted 500 mM 
CHOL-LPs showed more staining of siRNA than in the disrupted CHEMS-LPs; however, 
the staining near the well in the disrupted CHEMS-LPs indicates incomplete release of 
bound siRNA and further studies of the binding potential of CHOL- and CHEMS-LPs are 
needed. 
The amount of fluorescent non-targeting #5 siRNA bound to the liposomes was 
quantified using fluorescence spectroscopy with a Biotek Synergy plate reader 
containing a red (530/590) filter cube (Winooski, VT). The concentration of bound siRNA 
was estimated using a standard curve of serial siRNA dilutions. A standard curve with 
siRNA and Triton X-100 was also created to account for the interference of Triton X-100 
in the fluorescence reading. Intact and disrupted samples of the CHOL-LPs and CHEMS-
LPs at a concentration of 500 mM were examined. The 5 mM samples were not 
analyzed because the concentration of siRNA in the liposomes was too low to be 
detected, as seen in the gel shift assay. Binding/loading efficiency, as determined by 
siRNA concentration correlating to intensity of fluorescence, was higher in the CHOL-LPs 
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than in the CHEMS-LPs (Table 5.2). Fluorescence quenching due to tight interactions 
between protonated CHEMS and slightly negatively-charged DPPC in the lipid bilayer 
may have influenced the apparent bound siRNA concentration. 
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5.2.4 Cellular Uptake of Liposomes 
CHOL-LPs mediated uptake of Nile Red and fluorescent non-targeting #5 siRNA 
into OVCAR3-TR cells after 4- and 8-hour treatment with 50 µM of liposomes. 
Fluorescence microscopy was used to visualize the intracellular accumulation of the 
cholesterol-containing liposomes (Fig. 5.4). As the length of treatment increased, the 
cellular uptake of the liposomes also increased, as demonstrated by the increase in red 
fluorescence in the 8-hour treatment compared to the 4-hour treatment.  
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Cellular uptake and co-localization of the CHOL-LPs and CHEMS-LPs loaded with 
fluorescent siRNA was also examined in OVCAR3-TR cells using immunofluorescence. 
The liposomes are expected to enter the cells through endocytosis due to incorporation 
of cationic lipids and pegylation, so an early endosomal marker (EEA1) was used to label 
endosome locations in the cell, as shown by green fluorescence. The CHOL-LPs 
experienced increased cellular uptake compared to the CHEMS-LPs (Fig. 5.5). However, 
final conclusions cannot be made about the uptake until further studies are done to 
analyze the binding efficiency of siRNA in CHEMS-LPs without interference or quenching 
from any of the lipids. Due to the lack of fluorescent labeling of the liposomes 
themselves, our uptake visualization is based solely on the fluorescence of siRNA. Co-
localization of the CHOL- and CHEMS-LPs with endosomes was analyzed using ImageJ. 
Little co-localization was visualized in either liposomes (Fig. 5.6), indicating a different 
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mechanism of cellular uptake than endocytosis, likely due to the ability of cationic lipids 






In this study, we identified potential gene targets in the development of drug-
resistance in ovarian cancer cells. We developed two formulations of liposomes with the 
ability to encapsulate paclitaxel and bind siRNAs for combinatorial delivery to drug-
resistant ovarian cancer cells. The concurrent delivery strategy provides the potential to 
knockdown genes related to resistance and re-sensitize cells to paclitaxel to improve the 
drug’s efficacy in resistant ovarian cancer cells. Also, liposomal delivery may allow for a 
smaller effective drug dosage with limited systemic toxicity compared to standard 
intravenous chemotherapy. 
Our results identified potential gene targets involved in the development of 
paclitaxel-resistance in ovarian cancer cells. Gene expression and microarray analysis 
have been useful in discovering genes which might play a role in cisplatin-resistance in 
ovarian cancer cells in vitro and in patient samples [100,101]. Similarly, paclitaxel 
resistance has been studied through small-scale analysis of gene expression in multidrug 
cross-resistance [102]. However, array analysis of gene expression in paclitaxel-resistant 
ovarian cancer has yet to be explored on its own.  The results of the siRNA 
array/paclitaxel MTS assay demonstrated five different siRNAs significantly increased 
anticancer effects upon transfection and paclitaxel treatment compared to paclitaxel 
treatment alone.  The identified gene targets, ABCB1, JAK2, and CFLAR, are related to 
different functions in the cell, confirming the complexity of drug-resistance 
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development and treatment. ABCB1, encodes for an efflux transporter which mediates 
the efflux of chemotherapeutics in cells. JAK2 is a kinase in a signaling pathway 
responsible for promoting cell proliferation and survival. CFLAR is a regulating protein 
involved in the apoptosis pathways. This experiment validated the need to target 
multiple pathways when treating drug-resistance in ovarian cancer. The three siRNAs 
with the greatest anticancer effects have been chosen as therapeutic targets and will be 
loaded into the liposomal delivery system in combination with paclitaxel in the future 
for in vitro cytotoxicity studies.  
After determination of gene targets, liposomes were synthesized. We 
characterized the liposomes by evaluating size, polydispersity index, and surface charge 
of the different formulations. The mean particle size of both formulations was about 
100 nm and the PDI ranged from 0.214-0.252, indicating uniformly sized and 
monodisperse particles. CHEMS-LPs possessed smaller mean particle size and PDI, likely 
due to the presence of interactions with protonated CHEMS and DPPC creating tightly-
bound particles [103]. The zeta-potential of the liposomes ranged from +20 to +30 mV, 
indicating stable, cationic particles due to the incorporation of cationic lipids and 
protonation of CHEMS in aqueous media.   
Paclitaxel loading efficiency and siRNA binding efficiency were analyzed after 
initial characterization studies. Paclitaxel loading efficiency was almost identical in the 
CHOL-LPs and CHEMS-LPs, with values of about 80%, indicating efficient drug loading 
and encapsulation. siRNA binding did differ between the liposome formulations, with 
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more siRNA binding shown in the CHOL-LPs than in the CHEMS-LPs. The difference in 
siRNA concentration in the liposomes could be due to quenching of the fluorescent 
siRNA in the CHEMS-LPs due to electrostatic interactions between CHEMS and DPPC. To 
ensure proper binding of siRNA in the CHEMS-LPs, we would need to control the 
formation of the liposomes and encourage the siRNA to bind inside, possibly by 
introducing the siRNA into a system in which CHEMS is not protonated. The siRNA 
binding could also be lower in the CHEMS-LPs, especially the disrupted samples, due to 
formation of self-aggregates by CHEMS. These self-aggregates could be preventing the 
release of siRNA during disruption, decreasing the apparent amount of siRNA. Further 
RNA quantification studies can be done to eliminate the interference from the lipids. 
Both of these theories are also validated through the gel shift assay because the 
intact CHEMS-LPs sample demonstrated stained siRNA inside the well, indicating the 
stain was able to reach the siRNA. Also, the CHEMS-LPs disrupted with Triton X-100 
showed a fainter band of stained siRNA than the CHOL-LPs and staining of siRNA near 
the well, showing some siRNA was still bound to lipid components even after disruption. 
The gel shift assay indicated siRNA protection due to the lack of free siRNA present in 
the intact liposomes. Further studies of siRNA binding ability in the CHEMS-LPs are 
needed in order to create a potential pH-sensitive alternative to the CHOL-LPs. CHEMS-
containing liposomes have not commonly been used for combination delivery systems, 
though they are popular for single drug delivery systems. Thus, more extensive studies 
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on the N/P ratios and charge ratios would be beneficial to increase siRNA binding 
efficiency in the CHEMS-LPs.  
Cellular uptake of Nile Red and fluorescent siRNA by drug-resistant ovarian 
cancer cells was mediated by the cholesterol-containing liposomes in 4- and 8-hour 
treatments. Uptake increased with increased treatment length. Immunofluorescence 
was utilized to analyze cellular uptake and co-localization of the CHOL-LPs and CHEMS-
LPs loaded with fluorescent siRNA in endosomes after 2-hour treatments. The liposomes 
mediated uptake in both treatments; however, greater uptake was visualized with the 
CHOL-LPs than the CHEMS-LPs. The decrease in fluorescence from siRNA could be 
correlated to the lower binding of siRNA in CHEMS-LPs than CHOL-LPs or due to 
quenching and interference of lipids. Low amounts of co-localization of the fluorescent 
siRNA in endosomes indicates an uptake mechanism other than endocytosis. By 
fluorescently labeling the liposomes instead of only the loaded therapeutics, the uptake 
of the liposomes can be visualized with fluorescence microscopy [104]. 
In order to determine the potential of the liposomes and selected siRNAs as an 
effective therapy for drug-resistant ovarian cancer, studies examining the ability of the 
liposomes to mediate silencing of the targeted siRNAs need to be conducted. 
Quantification of gene targets in wild-type and resistant ovarian cancer cells can be 
analyzed with western blotting and RT-PCR to ensure upregulation of genes in resistant 
cells. Also, knockdown efficiency of the chosen siRNA and resulting viability can also be 
explored. Cytotoxicity assays, including MTT assay, wound healing assay, and flow 
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cytometry for live/dead analysis, can help demonstrate the therapeutic potential of the 




Overall, we have identified three gene targets that may be involved in the 
development of paclitaxel-resistance in ovarian cancer cells from a siRNA array. The 
three siRNA with the greatest anticancer effects will be used as therapeutics in 
combination with paclitaxel in our liposome delivery system. After liposome synthesis, 
we confirmed uniform sizing, monodisperse particles, and stable cationic liposomes 
through characterization studies. We demonstrated efficient loading of paclitaxel and 
protection of bound siRNA in both liposome formulations. In addition, liposomes 
mediated uptake of Nile Red and fluorescent siRNA or fluorescent siRNA alone into 
ovarian cancer cells. The characterization studies of the liposomes indicate their 
potential as a combination delivery system. However, further studies need to be done 
to increase siRNA binding efficiency and examine the pH-sensitive release of CHEMS-
LPs. Also, in vitro and in vivo cytotoxicity studies are necessary to confirm the efficacy of 
the combinatorial liposome delivery system.  
Liposomal combination therapies are gaining popularity as potential treatments 
for drug-resistant cancer. Combinatorial delivery can synergistically enhance the efficacy 
of therapeutics when delivered to drug-resistant cells by simultaneously re-sensitizing 
and treating cancer cells. The liposomes developed in this study show promise as 
combination delivery systems upon optimizing siRNA binding and release profiles of the 
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particles. We aim to create a more effective alternative to current treatments for drug-




In order to further determine the therapeutic potential of the developed 
liposomal combination delivery systems, gene target expression, release profiles, and 
cytotoxicity must be analyzed for both liposomes. Expression of the selected target 
genes, ABCB1, JAK2, and CFLAR, must be studied in both wild-type and paclitaxel-
resistant ovarian cancer cells. Western blotting will be utilized to compare the 
expression of the targeted genes in OVCAR3 and OVCAR3-TR ovarian cancer cells, where 
upregulation of the gene targets in the OVCAR3-TR cells indicates a potential 
involvement in paclitaxel-resistance. To further quantify the targeted genes in both cell 
lines, reverse-transcription polymerase chain reaction (RT-PCR) will be used to 
determine the RNA transcript levels.  
After quantifying expression of gene targets in the OVCAR3 and OVCAR3-TR 
ovarian cancer cells, siRNA knockdown will be used to determine the efficiency of the 
siRNAs in silencing the selected genes. Western blotting and RT-PCR will be used to 
quantify protein and RNA levels in untreated OVCAR3-TR cells and in cells transfected 
with siRNAs correlating to targeted genes. The quantification of gene target expression 
is vital in confirming the therapeutic potential of the selected siRNAs in targeting 
mechanisms of paclitaxel-resistance.  
To further characterize the CHOL- and CHEMS-LPs, release profile studies will be 
completed to analyze the pH-sensitivity of CHEMS-LPs compared to CHOL-LPs. Release 
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studies using release media of varying pHs will be used to determine the characteristics 
of pH-responsive behavior in CHEMS-LPs in environments with similar pH to tumor 
microenvironments. Other studies include scanning electron microscopy (SEM) and 
conductivity studies of the liposomes in various pHs can be used to analyze the change 
in shape and stability of the liposomes due to pH changes, indicating pH-sensitivity. In 
addition, to improve siRNA quantification in the CHEMS-LPS, it is necessary to eliminate 
interference or quenching due to the presence of lipids.  
To quantify siRNA directly, a Take 3 microplate will be used in the Biotek Synergy 
plate reader. Also, a Ribogreen assay, a method using an ultra-sensitive fluorescent 
molecule to quantify small amounts of RNA without interference from lipids. If siRNA 
quantification studies demonstrate lower siRNA binding/loading efficiencies in the 
CHEMS-LPs, optimization of the size/charge ratio and N/P ratio of the liposomes will 
take place.  
Immunofluorescence will be done at a later time point, 4 hours, to examine 
uptake mechanisms and track the localization and escape of both types of liposomes. To 
better visualize the liposomes, liposomes will be fluorescently labeled instead of the 
liposomal contents. A fluorescent tracker, like BODIPY FL or LysoTracker can then be 
used to examine the mechanism of uptake of the liposomes.  
Additional work on the synthesis methods of the liposomes will include 
developing a method to improve stability of liposomes and a method of long-term 
storage. Currently, synthesis of the liposomes is not optimal as liposomes are 
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synthesized weekly, so developing a method of longer storage is needed. Synthesis of 
liposomes will also expand to include targeting moieties and surface modifications to 
increase specificity, cellular uptake, and intracellular release and accumulation.  
Finally, cytotoxicity assays will be completed in vitro to examine the therapeutic 
potential of the delivered siRNAs and paclitaxel, alone and in combination. Cell viability 
assays, specifically MTT assays, will be used to determine viability of cells transfected 
with siRNAs alone, treated with paclitaxel alone, or transfected and treated with siRNAs 
and paclitaxel. The liposomal delivery systems will be analyzed to confirm the synergistic 
anticancer effects of simultaneous siRNA knockdown and paclitaxel treatment. Wound 
healing assays will be used to determine changes in motility of OVCAR3-TR ovarian 
cancer cells after liposomal treatment. Flow cytometry will be used for live/dead 
analysis of OVCAR3-TR cells treated with various concentrations of paclitaxel 
encapsulated in liposomes. Western blotting and RT-PCR will be used to confirm the 
knockdown of targeted genes after delivery of siRNAs by the liposomal delivery systems. 
Through these future steps, the therapeutic potential of the liposomal delivery systems 
as a combination therapy to combat paclitaxel-resistance in ovarian cancer.  
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